ARCHIVES

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

This article is from The Cancer Letter archive.

Vol. 21 No. 43 | November 10, 1995

Download PDF Visit The Full Archive

Related Articles

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996

Pediatric Oncology Groups Plan To Merge, Citing Greater Cost Efficiencies, Leverage

August 7, 1998

Report Calls For Reinvigorated Cancer Program With Increased Funding, Greater Collaboration.

May 9, 2008

Mihich Subcommittee Recommendations For Augmenting Agents In BRMP Described

December 7, 1979

Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates

March 26, 2004

BMS Control Of Billion-Dollar Taxol Market Facing Court Challeges By Competitors

May 29, 1998